Literature DB >> 7542240

A study of the intracellular routing of cytotoxic ribonucleases.

Y Wu1, S K Saxena, W Ardelt, M Gadina, S M Mikulski, C De Lorenzo, G D'Alessio, R J Youle.   

Abstract

Several ribonucleases serve as cytotoxic agents in host defense and in physiological cell death pathways. Although certain members of the pancreatic ribonuclease A superfamily can be toxic when applied to the outside of cells, they become thousands of times more toxic when artificially introduced into the cytosol, indicating that internalization is the rate-limiting step for cytotoxicity. We have used three agents that disrupt the Golgi apparatus by distinct mechanisms, retinoic acid, brefeldin A, and monensin, to probe the intracellular pathways ribonucleases take to reach the cytosol. Retinoic acid and monensin potentiate the cytotoxicity of bovine seminal RNase, Onconase, angiogenin, and human ribonuclease A 100 times or more. Retinoic acid-mediated potentiation of ribonucleases is completely blocked by brefeldin A. Ribonucleases appear to route more efficiently into the cytosol through the Golgi apparatus disrupted by monensin or retinoic acid. Intracellular RNA degradation by BS-RNase increased more than 100 times in the presence of retinoic acid confirming that the RNase reaches the cytosol and indicating that degradation of RNA is the intracellular lesion causing toxicity. As retinoic acid alone and Onconase are in clinical trials for cancer therapy, combinations of RNases and retinoic acid in vivo may offer new clinical utility.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7542240     DOI: 10.1074/jbc.270.29.17476

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  20 in total

1.  Induction of differentiation of leukaemic (HL-60) or prostate cancer (LNCaP, JCA-1) cells potentiates apoptosis triggered by onconase.

Authors:  H D Halicka; T Murakami; C N Papageorgio; A Mittelman; S M Mikulski; K Shogen; Z Darzynkiewicz
Journal:  Cell Prolif       Date:  2000-12       Impact factor: 6.831

Review 2.  Cancer chemotherapy--ribonucleases to the rescue.

Authors:  P A Leland; R T Raines
Journal:  Chem Biol       Date:  2001-05

3.  Changing the net charge from negative to positive makes ribonuclease Sa cytotoxic.

Authors:  Olga N Ilinskaya; Florian Dreyer; Vladimir A Mitkevich; Kevin L Shaw; C Nick Pace; Alexander A Makarov
Journal:  Protein Sci       Date:  2002-10       Impact factor: 6.725

4.  Secretory ribonucleases are internalized by a dynamin-independent endocytic pathway.

Authors:  Marcia C Haigis; Ronald T Raines
Journal:  J Cell Sci       Date:  2003-01-15       Impact factor: 5.285

5.  Secretion of ribonucleases by normal and immortalized cells grown in serum-free culture conditions.

Authors:  M Moenner; E Hatzi; J Badet
Journal:  In Vitro Cell Dev Biol Anim       Date:  1997 Jul-Aug       Impact factor: 2.416

6.  Ribonuclease A variants with potent cytotoxic activity.

Authors:  P A Leland; L W Schultz; B M Kim; R T Raines
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-01       Impact factor: 11.205

Review 7.  Onconase and amphinase, the antitumor ribonucleases from Rana pipiens oocytes.

Authors:  W Ardelt; K Shogen; Z Darzynkiewicz
Journal:  Curr Pharm Biotechnol       Date:  2008-06       Impact factor: 2.837

Review 8.  Oligomerization of bovine ribonuclease A: structural and functional features of its multimers.

Authors:  Massimo Libonati; Giovanni Gotte
Journal:  Biochem J       Date:  2004-06-01       Impact factor: 3.857

9.  The cytotoxic ribonuclease onconase targets RNA interference (siRNA).

Authors:  Hong Zhao; Barbara Ardelt; Wojciech Ardelt; Kuslima Shogen; Zbigniew Darzynkiewicz
Journal:  Cell Cycle       Date:  2008-10-25       Impact factor: 4.534

10.  Eosinophil ribonucleases and their cutaneous lesion-forming activity.

Authors:  Douglas A Plager; Mark D P Davis; Amy G Andrews; Michael J Coenen; Terry J George; Gerald J Gleich; Kristin M Leiferman
Journal:  J Immunol       Date:  2009-08-28       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.